Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, today announced the appointment of Jim Faulkner, Ph.D., as chief technology officer, initially serving on an interim basis.
“Jim brings a specialized skillset and innovative technology experience at the start of what will be a year of momentum for Wugen,” said Kumar Srinivasan, Ph.D., M.B.A., president and chief executive officer of Wugen. “Jim has been instrumental in bringing more than 25 different therapeutics into the clinic, including multiple gene therapy and CAR-T assets. We remain diligently focused on the launch of our pivotal Phase 2 trial for WU-CART-007, the first CD7-targeted allogeneic CAR-T cell therapy. Jim’s experience will be critical as we advance that program.”
“I was immediately impressed by this team’s laser-focused effort to advance WU-CART-007. The data they have generated suggest WU-CART-007 has great potential,” Dr. Faulkner said. “I’m excited to be joining a company that shares my dedication and commitment to moving the field of cell and gene therapy forward, and I’m especially excited about the opportunity to work with the team to pioneer novel allogeneic cell therapies.”
Dr. Faulkner’s vast experience in the field includes consulting and biotechnology company leadership roles. Currently, Dr. Faulkner operates an independent consultancy company advising clients on diverse aspects of gene and cell therapy development and serves as a non-executive director on several boards, including the Cell and Gene Therapy Catapult, based in London. A former venture partner at Apple Tree Partners (ATP), Dr. Faulkner simultaneously served as chief technical officer at Ascidian Therapeutics, a gene therapy company developing novel Exon Editing technology. Earlier, he was head of product delivery at Autolus Ltd, a clinical-stage CAR-T company spun out of University College London (UCL), where he was a member of the core senior team that advanced the company from start-up to successful IPO in three years.
Dr. Faulkner holds a degree in biotechnology from the University of Leeds in the U.K. and completed a Ph.D. in Molecular Biology while at the Centre for Applied Microbiology and Research. After starting his career at British Biotech, he joined GlaxoSmithKline, where he held a series of increasingly senior roles in biopharmaceutical development.
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream formerly known as CIO News LinkedIn Account | The Mainstream formerly known as CIO News Facebook | The Mainstream formerly known as CIO News Youtube | The Mainstream formerly known as CIO News Twitter
About us:
The Mainstream formerly known as CIO News is a premier platform dedicated to delivering latest news, updates, and insights from the tech industry. With its strong foundation of intellectual property and thought leadership, the platform is well-positioned to stay ahead of the curve and lead conversations about how technology shapes our world. From its early days as CIO News to its rebranding as The Mainstream on November 28, 2024, it has been expanding its global reach, targeting key markets in the Middle East & Africa, ASEAN, the USA, and the UK. The Mainstream is a vision to put technology at the center of every conversation, inspiring professionals and organizations to embrace the future of tech.
